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COMMENTARY
Clinical protein science developments 
for patient monitoring in hospital central 
laboratories
Johan Malm1,2,3 and György Marko‑Varga2,3,4*
Abstract 
Patient care relies heavily on standardized tests performed in hospital laboratories, typically including clinical chemis‑
try, pathology and microbiology. With the introduction of personalized medicine tremendous efforts have been made 
to identify new biomarkers of disease with various omics technologies, often including mass spectrometry. In order 
to validate new biomarkers and perform clinical studies high quality biobank samples are of key importance. In this 
editorial different aspects of mass spectrometry in future personalized medicine are discussed.
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Editorial
Every day thousands and thousands of human tissue 
samples are sent to hospital laboratories for analysis. The 
results constitute the major source of diagnostic, prog-
nostic and disease monitoring information on patient 
health, and forms the basis for the decision making by 
clinicians. The healthcare sector relies on standardized 
assays that can be made comparable in both Lund, Swe-
den, as well as, e.g. in Hyderabad, India. Today in our 
globalized healthcare driven society, the instrumental 
companies can ship, and implement any assay in a labo-
ratory in any continent. Assay standards are made avail-
able that allows results from different laboratories to be 
compared, thus building a joint world wide resource for 
patient care. The actual measurement and its analytical 
characteristics is the key for patient diagnosis, and dis-
ease status determination. Compared to the total cost 
of patient care, laboratory based information is often 
relatively cheap. Tissue samples, in most cases blood, 
are sent to the hospital laboratory not only from dif-
ferent hospital wards but also from e.g. primary care 
units, private practices, and occupational health clin-
ics. Already today, and even more tomorrow, a substan-
tial number of these samples will also be transferred to 
and stored in large scale Biobanks [1]. Some of the most 
common routine tests in clinical chemistry laborato-
ries are; CBC (complete blood count), electrolytes, hor-
mones, coagulation parameters, disease specific protein 
biomarkers and plasma biomarker proteins. In clinical 
microbiology laboratories the quantitatively dominating 
tests, performed on e.g. urine, blood and swab cultures, 
are ordered to identify the microorganism causing infec-
tion. These tests are often carried out in conjunction with 
susceptibility testing to determine specific antibiotics 
that will inhibit the growth of the microbe. In addition, 
the clinical pathology laboratories process tissue samples 
subsequently being subject to microscopic evaluation 
for diagnosing disease. Hospital laboratories have used 
mass spectrometry for many years, mainly for the anal-
ysis of therapeutic drugs and drugs of abuse, but lately 
also as multiplex assay analyzers for endogenous mark-
ers. As mass spectrometer platforms have improved over 
time, with an increase in both sensitivity and resolving 
power, and with an easier to use approach, there has been 
increasing expectations that many of the routine hospital 
lab analyses would be performed using mass spectrome-
try technology, instead of e.g. immunochemical methods. 
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Not only mass spectrometry but also other ‘omics tools’ 
have become more widely and affordably available, 
and these new technologies form the basis for an accu-
rate and versatile monitoring of personalized medicine 
treatments.
During the last decades tremendous efforts have been 
made to identify and introduce novel biomarkers, espe-
cially cancer biomarkers, in clinical medicine. These 
biomarkers, whether biomarkers for cancer or other 
diseases, may be of varying molecular types, such as; 
proteins, DNA, RNA, and metabolites, are found in e.g. 
blood, urine or other tissue samples. In spite of improved 
technology capabilities, the introduction of what is often 
called “precision medicine” or “personalized medicine” 
in hospital routine laboratories has been slower than 
expected, mainly for two reasons;
  • the degree of automation
  • the interpretation of data.
Most of today’s routine analyses are fairly cheap, highly 
automated and have short turn-around times. The result-
ing outcome is in most cases, easily interpreted. Mass 
spectrometry on the other hand has traditionally been 
labor intensive and the interpretation of the resulting, 
often, complex data a bottleneck. However, the differ-
ent ‘omics tools’, and in particular mass spectrometry, 
have become faster and more easy to use. The instrument 
purchase still remains the major cost, while the running 
costs still are low in comparison to ELISA platforms. 
With dedicated assays, the data can be easily handled as 
relative or absolute measures in patient samples.
One of the most widely used omics technology plat-
forms is mass spectrometry based detection of somatic 
gene mutations using the Sequenome DNA mass-array 
technology. Here matrix-assisted laser desorption ioniza-
tion time of flight (MALDI-TOF) technology has been 
adapted to high throughput screening. One of the most 
recent, ‘new’ fields using mass spectrometry in routine 
diagnostics is the identification and typing of bacteria, 
especially after the approval by FDA of two MALDI-
TOF–MS based platforms [2, 3]. By the use of MALDI 
mass spectrometry technology many cultivable micro-
organism in clinical samples can be identified, and mass 
spectrometry based diagnostics can be used for rapid 
hospital laboratory diagnosis of common organisms 
including those that are difficult to culture. Fast and spe-
cific identification of microorganisms will be even more 
important in the future due to the increasing problems 
with antibiotic resistance. In patients with sepsis, one of 
the leading causes of death in non-coronary intensive 
care units, early treatment is of utmost importance and 
often impacts patient outcome. Recently, clinical reports 
position sepsis as a major challenge to the healthcare sec-
tor and to our society. Sepsis patients constitute a health-
care problem with the same magnitude as a major part of 
cancer patients per year, partly due antibiotic resistance. 
Consequently, rapid identification of the blood stream 
infections, and the identity of the particular microor-
ganism causing the disease is a prerequisite for initiating 
adequate antibiotic therapy. There are dedicated kits for 
Sepsis; The MALDI Biotyper Sepsityper®, which enable a 
proteomic profile to be established, with high resolution 
mass spectrometry that applies sequence libraries for a 
positive identification of various bacteria directly from 
positive blood cultures. Another example of proteomics 
based identification of microorganisms is the identifica-
tion of mycobacteria using the “Mycobacteria Library”, 
which currently can manage the positive identity of 159 
out of the 169 known species of today, applying high 
end bioinformatics software. Following the regulatory 
guidelines, the sample is submitted to the Biotyper mass 
spectrometry platform for screening and identification 
of blood samples, the diagnosis is established in less than 
30 min after detection of a positive blood culture. Typi-
cally, 96 samples can be fully analyzed in one cycle period 
using MALDI Mass Spectrometry technology as a high 
throughput platform [4].
In the hospital pathology laboratory the histopatho-
logical diagnosis has long been performed by haematoxy-
lin and eosin stained tissue samples. This method is now 
routinely complemented by immunohistochemistry and 
often also by electron microscopy and molecular tech-
niques. During the last two decades mass spectrometry 
imaging (MSI) has been used for direct analysis of tis-
sue sections. Especially MALDI links molecular analysis 
to traditional histology. MSI may add information to the 
histopathological analysis, confirm the diagnosis and aid 
in the choice of treatment [5]. Our knowledge of diseases 
is being advanced in large population-based studies, and 
the use of data from these epidemiological resources will 
highly impact our ability to both model and solve disease-
related questions in the future. Clinical samples represent 
a valuable resource not only in routine patient care, but 
also for investigating the many factors that drive human 
biology in various disease settings. Biomarkers present 
in clinical samples bring important read-outs of health 
and disease. When this data is combined with other 
types of patient information, it can aid decision making 
by physicians in applying the optimal patient treatment 
procedure. Improved analytical performance character-
istics requires high quality samples for reliable results. 
There are many steps in sample processing, storage, and 
management that need to be understood and pursued 
in R&D operations. These work flows and integrations 
provide not only preservation of the desired analytes in 
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the sample, but are also a prerequisite to comply with 
the moral and legal framework required for human sub-
ject protection irrespective of where the samples have 
been collected. Laboratory medicine should make a great 
effort in todays community work to align and standard-
ize the methodology of endogenous biomolecule deter-
mination. It should include sample storage performed in 
biobanks, and the necessary frameworks of human sub-
ject protection that includes informed consent, and insti-
tutional review of the studies being performed.
Global healthcare is under pressure to meet the 
demands from patients to improve efficiency, especially 
in treatment of cancer diseases. Societies have difficulties 
in managing an increasing burden of healthcare costs. 
New drug characterization assays are central in provid-
ing evidence to the specificity and selectivity of drugs. 
Targeted drug development requires mode of drug action 
mechanistic studies in order to get approval from the 
FDA. Large scale protein sequencing studies are under-
taken to discover different molecular protein forms, i.e. 
“Proteoforms” that can be linked to disease, and treat-
ment processes, both as drug targets as well as biomark-
ers. Multi-dimensional liquid chromatography (MDLC) 
separation systems within automated platforms are built 
with on-line as well as off-line liquid phase systems, 
applied in proteo-genomic studies applying both cation-
exchange and anion exchange mechanisms. A recent 
Cell paper by the ISB-team in Seattle [6], describes the 
SRM-Atlas, a milestone achievement, which is a com-
pendium of assays that enables quantification of 99.7% 
of the 20,277 annotated human proteins. This includes a 
selection of splice variants, non-synonymous SNPs, and 
N-glycosylated proteins, by selected reaction monitoring 
(SRM). This resource enables the accurate detection and 
quantification of any known or predicted human protein. 
We envision that protein quantification by MS-platforms 
will constitute a paradigm shift in hospital laboratories 
worldwide; targeted analysis will be made by selected 
reaction monitoring “SRM” assays. These SRM assays are 
also easy to multiplex, whereby a number of 10–100 pro-
tein biomarkers can be analysed in a single assay cycle. 
There are already instruments in place in hospitals being 
tested as pilot units in a high throughput fashion for the 
quantitative analysis of proteins. The ageing population 
world wide will generate more patients who expect health 
services to provide fast and accurate diagnostic tools—
mass spectrometry based assays can be expected to play 
a major role in tomorrows hospital laboratories. But not 
only for analysis of disease—probably also for analysis of 
health. There is a trend where measuring subjective well-
being and people’s quality of life is fundamental when 
assessing the progress of societies. These measurements 
can be expected to include screening in central hospital 
laboratories, e.g. in the analysis of blood plasma, the 
most easily accessible human sample.
In conclusion, we envisage a future where a further 
technology development positions mass spectrometry 
as a key technology in novel and highly automated ana-
lytical platforms in hospital routine laboratories, that will 
be used in diagnosis, prognosis and monitoring of dis-
ease—and health. The developments are seen within cur-
rent applications of personalized medicine strategies, by 
matching specific disease genotypes and phenotypes with 
specific pharmaceutical drug treatment. The expansion of 
this treatment paradigm into other diseases will further 
lead to new opportunities within the diagnosis and treat-
ment of diseases, particularly for “Precision Medicine”.
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